［1］Naval D，Yanis B，Hagop K，et al.A phase I/II Study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia［J］.Clin Cancer Res，2015，21(12)：2704-2714.
［2］Mathisen MS，Kantarjian H，Thomas D，et al.Acute lymphoblastic leukemia in adults：encouraging developments on the way to higher cure rates［J］.Leuk Lymphoma，2013，54：2592-2600.
［3］Piccaluga PP，Arpinati M，Candoni A，et al.Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia［J］.Leuk Lymphoma，2011，52：325-327.
［4］Kantarjian H，Thomas D，Jorgensen J，et al.Inotuzumab ozogamicin，an anti-CD22-calicheamicin conjugate，for refractory and relapsed acute lymphocytic leukaemia：A phase 2 study［J］.Lancet Oncol，2012，13：403-411.
［5］Thomas DA，Sarris AH，Cortes J，et al．Phase II study of sphingo-somal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia［J］．Cancer，2006，106：120-127．
［6］Zhao J，Wang C，Song Y，et al.Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy［J］.Int J Gen Med，2015，12(8)：211-214.
［7］Maino E，Bonifacio M，Scattolin AM，et al.Immunotherapy approaches to treat adult acute lymphoblastic leukemia［J］.Expert Rev Hematol，2016，9(6)：563-577.
［8］Konopleva M，Thall PF，Yi CA，et al.Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia［J］.Haematologica，2015，100(7)：927-934.
［9］Murphy SB，Bowman WP，Abromowitch M，et al.Results of treatment of advanced-stage Burkitt's Lymphoma and B cell(sig+) acute lymphocytic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose-methotrexate and cytarabine［J］.Clin Oncol，1986，4：1732-1739.
［10］Fader1 S，Kantarjian HM，Thomas DA，et al.Outcome of Philadelphia chromosomepositive adult acute lymphoblastic leukemia［J］.Leuk Lymphoma，2000，36：263-273.
［11］Alwan AF，Matti BF，Naji AS，et al.The efficacy of fludarabine，high dose cytosine arabinoside with granulocyte colony stimulating factor (FLAG) Protocol as salvage therapy for refractory/relapsed acute leukemias in adult iraqi patients［J］.Indian J Hematol Blood Transfus，2014，30(4)：231-235.
［12］Qian LR，Fu W，Shen JL.Agents for refractory/relapsed acute lymphocytic leukemia in adults［J］.Eur Rev Med Pharmacol Sci，2014，18(17)：2465-2474.
［13］Litzow MR.The therapy of relapsed acute leukemia in adults［J］.Blood Rev，2004，18(1)：39-63．
［14］Bao L，Jiang B，Huang XJ，et al.Treatment of refractory and relapsed acute lymphoblastic leukemia in adults［J］.J Peking University(Health Sciences)，2005，37(4)：355-357.［鲍立，江滨，黄晓军，等．难治性复发成人急性淋巴细胞白血病的治疗［J］．北京大学学报(医学版)，2005，37(4)：355-357.］
［15］Xie XS，Wan DM，Chen SQ，et al.HyperCVAD regimen in the treatment of 18 cases of relapsed adult acute lymphoblastic leukemia［J］.Leukemia lymphoma，2009，18(2)：107-108.［谢新生，万鼎铭，陈绍倩，等.HyperCVAD方案治疗复发成年人急性淋巴细胞白血病18例［J］.白血病·淋巴瘤，2009，18(2)：107-108.］